Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prucalopride for Cognitive Functioning in Schizophrenia
NCT06474286Not yet recruiting
- Sponsor
- University of Pittsburgh
- Start
- May 2027
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of prucalopride in schizophrenia, sponsored by University of Pittsburgh. Primary endpoints: Positive and Negative Syndrome Scale at 4 weeks, Brief Assessment of Cognition in Schizophrenia - List learning at 4 weeks and 4 more. Planned start May 2027; status: not yet recruiting.
02
Drugs
prucalopride
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06474286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06474286.